Browsing by Author "Inurrigarro, G"

Now showing 1 - 2 of 2

Status of breast cancer in Latin American: Results of the breast cancer revealed initiative
(Elsevier Ireland Ltd, 2023) Ayala, N; Barchuk, S; Inurrigarro, G; Celano, C; Soriano-García, JL; Bolaños, P; Mohs-Alfaro, M; Tapia-González, H; Perez-Martinez, R; Samtani, S; Alvarado-Cabrero, I; Villarreal-Garza, C; Tamez-Salazar, J; Magallanes-Garza, GI; Vazquez, D; Castro, J; Gómez-Macías, GS; Ferrigno, A; Morante, Z; Vilchez, S; Cotrina, JM; Doimi, F; Santander, G; Acevedo, C; Ortega, V; Lavista, F; Richter, L; Gianella, M; Paredes ,M; Flores-Balcázar, CH; Pinto, JA; Gomez, HL
The Breast Cancer Revealed initiative was designed and conducted to know the status of breast cancer at each point of breast cancer care, through i) prevention, ii) detection, iii) diagnosis, iv) treatment, and iv) the capacity of our health systems. The expert panel from 11 Latin American countries identified several strategies and proposed high impact priorities, including implementation of prevention policies, improve primary healthcare capacity for breast cancer screening, have adequate infrastructure to make effective and timely diagnoses, have a multidisciplinary team in the treatment process, access to a variety of treatments for all types of patients, have a coordinated and articulated system from primary care to specialized hospital. In a region with limited resources, prioritization in high-impact strategies for breast cancer control could lead to improved clinical outcomes and quality of life for our patients.
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
(Nature Publishing Group, 2021) El Bairi, K; Haynes, HR; Blackley, E; Fineberg, S; Shear, J; Turner, S; de Freitas, JR; Sur, D; Amendola, LC; Gharib, M; Kallala, A; Arun, I; Azmoudeh-Ardalan F; Fujimoto, L; Sua, LF; Liu, SW; Lien, HC; Kirtani, P; Balancin, M; El Attar, H; Guleria, P; Yang WShash, E; Chen, IC; Bautista, V; Do Prado Moura, JF; Rapoport, BL; Castaneda, C; Spengler, E; Acosta-Haab, G; Frahm, I; Sanchez, J; Castillo, M; Bouchmaa, N; Md Zin, RR; Shui, R; Onyuma, T; Yang, W; Husain, Z; Willard-Gallo, K; Coosemans, A; Perez, EA; Provenzano, E; Ericsson, PG; Richardet, E; Mehrotra, R; Sarancone, S; Ehinger, A; Rimm, DL; Bartlett, JMS; Viale, G; Denkert, C; Hida, AI; Sotiriou, C; Loibl, S; Hewitt, SM; Badve, S; Symmans, WF; Kim, RS; Pruneri, G; Goel, S; Francis, PA; Inurrigarro, G; Yamaguchi, R; Garcia-Rivello, H; Horlings, H; Afqir, S; Salgado, R; Adams, S; Kok, M; Dieci, MV; Michiels, S; Demaria S; Loi, S; International Immuno-Oncology Biomarker Working Group
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.